• MustGrow outlined commercialization plans for mustard-derived biological crop inputs spanning biofertility, biocontrol, postharvest, and animal health applications.
• TerraSante biofertility targets U.S. high-value crops; product registered in key states; 2025 supply sold out with about 1,000 acres applied.
• TerraMG biocontrol registrations targeted for 2026/2027 in Canada and the U.S.; positioned as an organic alternative to soil fumigants.
• Exclusive Bayer license covers EMEA biocontrol registration; MustGrow expects upfront and milestone payments, then royalties after registration.
• Presentation cited 70,441,359 shares outstanding; fully diluted 91,914,368; market cap CAD 30 million; cash CAD 419,577 at March 31, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MustGrow Biologics Corp. published the original content used to generate this news brief on August 12, 2026, and is solely responsible for the information contained therein.